Investigating genetic factors in a rare lung cancer
Official title: Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma
Run by Sun Yat-sen University · NCT06801977 · Data updated 2026-11-12
This study is trying to find out if certain genes are linked to a rare lung cancer that mostly affects people in Asia by comparing the genetic information of patients with the disease to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 2 sites (Foshan, Guangdong and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2002 |
| Main results expected | June 30, 2025 |
| Study ends | December 31, 2030 |
| Registry record updated | January 30, 2025 |
| Trial ID | NCT06801977 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a pathological diagnosis of primary pulmonary lymphoepithelioma-like carcinoma.
✕Probably not a fit
Patients diagnosed with metastatic nasopharyngeal carcinoma or those with severe cardiovascular, liver, or kidney diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on primary pulmonary lymphoepithelioma-like carcinoma (pLELC), a rare form of lung cancer that primarily affects the Asian population. It aims to uncover genetic susceptibility loci and pathogenic genes associated with the disease through a genome-wide association study. By comparing genetic data from patients diagnosed with pLELC to healthy controls, the study seeks to provide new insights into the genetic mechanisms underlying this cancer. The research utilizes advanced genotyping techniques to analyze the genetic profiles of participants.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of the genetic factors contributing to primary pulmonary lymphoepithelioma-like carcinoma, potentially guiding future prevention and treatment strategies.
How similar studies have gone: While this study is novel in its focus on the genetic aspects of pLELC, similar genetic studies in other cancers have shown promising results in identifying susceptibility genes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Case: Inclusion criteria: The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma. Exclusion criteria: The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease. Controls: Inclusion criteria: The subject is in good physical condition and has a stable level of consciousness; Exclusion criteria: The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.
Where it's running
-
Foshan First People's Hospital
Foshan, Guangdong, China Recruiting -
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Wei-Hua Jia, MD
- Email: jiawh@sysucc.org.cn
- Phone: 86+020-87342327
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining immunotherapy and targeted therapy for rare bladder tumors
This study is testing a new combination of treatments for people with rare bladder tumors that have spread, to see if it helps them live longer and feel better.
-
Evaluating Pucotenlimab for treating pediatric lymphoepithelioma-like carcinoma
This study is testing a new treatment combining pucotenlimab with chemotherapy to see if it helps children and teenagers with a rare type of cancer called lymphoepithelioma-like carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.